Halozyme Therapeutics in (halo 0.25 03/01/27)
13F holders, Q1 2024 (March 31)10holders
$0.90avg. 13F price*
At the end of Q1 2024, 10 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings. The largest holders were Toronto Dominion Bank ($4.4M), Sonora Investment Management Group, LLC ($3.7M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($575K).
- Company
- Halozyme Therapeutics in (halo 0.25 03/01/27)
- CUSIP
- 40637HAD1
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $171K |
| Exits | 2 | $879K |
Ownership 10 holders
| Toronto Dominion Bank | 0.01% | No change | 5,000,000 | $4.4M |
| Sonora Investment Management Group, LLC | 0.29% | Reduce -0.5% | 4,222,000 | $3.7M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | Reduce -60.6% | 650,000 | $575K |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $533K |
| Cerity Partners LLC | 0.00% | Add +0.5% | 43,223 | $235K |
| Cetera Investment Advisers | 0.00% | New | 193,000 | $171K |
| Lanark Financial, Inc. | 0.00% | Reduce -51.9% | 13,000 | $11K |
| Northwestern Mutual Wealth Management Co. | 0.00% | Reduce -33.3% | 4,000 | $4K |
| Laffer Tengler Investments, Inc. | 0.00% | Reduce -3.8% | 2,107 | $2K |
| TD Private Client Wealth LLC | 0.00% | No change | 2,000 | $2K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.